Mesothelin Expression: Clinical Trials

2 trials of Mesothelin Expression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Completed 1

Follow Mesothelin Expression: new trials by email Literature Review of Mesothelin Expression trials Research Report on Mesothelin Expression

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma
Phase 1CompletedNational Cancer Institute (NCI)192019-08-292023-08-01
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
LMB-100, Nab-Paclitaxel, Mesothelin Expression - Neoplasms, Pancreatic Neoplasms
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)402016-08-032022-03-15

Conditions studied

Adenocarcinoma (1)  ·  Cholangiocarcinoma (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (2)

Countries

United States (2)

Top investigators

Christine C Alewine, M.D. (2)

Results publications

PMID 36208017, PMID 38706610